Immuneering (NASDAQ:IMRX) Announces Earnings Results, Misses Estimates By $0.01 EPS

Immuneering (NASDAQ:IMRX) issued its quarterly earnings results on Wednesday. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01), FiscalAI reports.

Immuneering Stock Performance

Shares of NASDAQ IMRX traded up $0.02 during mid-day trading on Friday, reaching $6.47. The company had a trading volume of 668,548 shares, compared to its average volume of 1,457,315. Immuneering has a twelve month low of $1.10 and a twelve month high of $10.08. The stock’s 50 day moving average is $6.84 and its 200-day moving average is $4.36. The stock has a market capitalization of $268.96 million, a PE ratio of -3.65 and a beta of 0.46.

Analyst Ratings Changes

Several analysts recently commented on IMRX shares. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Immuneering in a research note on Tuesday, September 30th. Mizuho set a $12.00 target price on Immuneering in a research report on Wednesday, October 29th. Chardan Capital reaffirmed a “buy” rating and set a $20.00 target price on shares of Immuneering in a report on Thursday. Needham & Company LLC lifted their price target on Immuneering from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, September 15th. Finally, Leerink Partners began coverage on shares of Immuneering in a report on Friday, October 31st. They set an “outperform” rating and a $15.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.50.

Insiders Place Their Bets

In other news, Director Peter Feinberg purchased 7,500 shares of the business’s stock in a transaction dated Friday, October 3rd. The stock was bought at an average cost of $6.67 per share, with a total value of $50,025.00. Following the purchase, the director directly owned 156,766 shares of the company’s stock, valued at approximately $1,045,629.22. This trade represents a 5.02% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders bought 20,800 shares of company stock valued at $143,754. Corporate insiders own 22.90% of the company’s stock.

Institutional Trading of Immuneering

Institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new position in Immuneering during the first quarter worth $32,000. XTX Topco Ltd acquired a new stake in Immuneering in the 2nd quarter worth $90,000. Dimensional Fund Advisors LP increased its holdings in shares of Immuneering by 46.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company’s stock worth $137,000 after purchasing an additional 6,196 shares during the period. Corient Private Wealth LLC acquired a new position in shares of Immuneering during the second quarter valued at about $215,000. Finally, Bridgeway Capital Management LLC lifted its stake in shares of Immuneering by 57.9% in the second quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock valued at $322,000 after buying an additional 35,000 shares during the period. 67.65% of the stock is currently owned by institutional investors and hedge funds.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.